Ypsomed sells pen needle and BGM business to MTD

Ypsomed has signed an agreement to transfer its pen needle and blood glucose monitoring systems businesses to Medical Technology and Devices S.p.A. (MTD). The businesses had sales of CHF 52 million in FY 2022/23.

“Ypsomed (SIX: YPSN) and Medical Technology and Devices S.p.A. (MTD) have signed an agreement on the transfer of the pen needle and blood glucose monitoring systems (BGMs) businesses.”ypsomed.com

• 2 sources
• ypsomed.comYpsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site - YpsomedMar 27, 2024
• medicaldevice-network.comYpsomed to sell pen needle and BGMs businesses to MTDArchana RaniMar 28, 2024

Summarized from public sources; check the original articles before acting on it.